Gastroenterology Service, Azienda Sanitaria Locale Barletta-Andria-Trani, Andria, Italy.
Division of Internal Medicine and Gastroenterology, Cristo Re Hospital, Rome, Italy.
United European Gastroenterol J. 2016 Aug;4(4):604-13. doi: 10.1177/2050640615617636. Epub 2015 Nov 13.
Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification has been recently developed for patients suffering from diverticulosis and diverticular disease.
We assessed retrospectively the predictive value of DICA in patients for whom endoscopic data and clinical follow-up were available.
For each patient, we recorded: age, severity of DICA, presence of abdominal pain, C-reactive protein and faecal calprotectin test (if available) at the time of diagnosis; months of follow-up; therapy taken during the follow-up to maintain remission (if any); occurrence/recurrence of diverticulitis; need of surgery.
We enrolled 1651 patients (793 M, 858 F, mean age 66.6 ± 11.1 years): 939 (56.9%) patients were classified as DICA 1, 501 (30.3%) patients as DICA 2 and 211 (12.8%) patients as DICA 3. The median follow-up was 24 (9-38) months. Acute diverticulitis (AD) occurred/recurred in 263 (15.9%) patients; surgery was necessary in 57 (21.7%) cases. DICA was the only factor significantly associated to the occurrence/recurrence of diverticulitis and surgery either at univariate (χ(2 )= 405.029; p < 0.0001) or multivariate analysis (hazard ratio = 4.319, 95% confidence interval (CI) 3.639-5.126; p < 0.0001). Only in DICA 2 patients was therapy effective for prevention of AD occurrence/recurrence with a hazard ratio (95% CI) of 0.598 (0.391-0.914) (p = 0.006, log rank test). Mesalazine-based therapies reduced the risk of AD occurrence/recurrence and needs of surgery with a hazard ratio (95% CI) of 0.2103 (0.122-0.364) and 0.459 (0.258-0.818), respectively.
DICA classification is a valid parameter to predict the risk of diverticulitis occurrence/recurrence in patients suffering from diverticular disease of the colon.
最近为患有憩室病和憩室疾病的患者开发了憩室炎和并发症评估(DICA)内镜分类。
我们回顾性评估了内镜数据和临床随访可用的患者的 DICA 预测价值。
对于每个患者,我们记录了:诊断时的年龄、DICA 严重程度、腹痛、C-反应蛋白和粪便钙卫蛋白检测(如果有);随访月数;随访期间维持缓解(如果有)的治疗;憩室炎的发生/复发;需要手术。
我们共纳入 1651 例患者(793 例男性,858 例女性,平均年龄 66.6±11.1 岁):939 例(56.9%)患者分类为 DICA 1,501 例(30.3%)患者为 DICA 2,211 例(12.8%)患者为 DICA 3。中位随访时间为 24(9-38)个月。263 例(15.9%)患者发生/复发急性憩室炎;57 例(21.7%)患者需要手术。DICA 是唯一与憩室炎和手术发生/复发显著相关的因素,无论是在单因素(χ(2)=405.029;p<0.0001)还是多因素分析中(危险比=4.319,95%置信区间(CI)3.639-5.126;p<0.0001)。仅在 DICA 2 患者中,治疗对预防 AD 发生/复发有效,危险比(95%CI)为 0.598(0.391-0.914)(p=0.006,对数秩检验)。基于美沙拉嗪的治疗可降低 AD 发生/复发和手术的风险,危险比(95%CI)分别为 0.2103(0.122-0.364)和 0.459(0.258-0.818)。
DICA 分类是预测患有结肠憩室病患者憩室炎发生/复发风险的有效参数。